{"id":"NCT00605085","sponsor":"Valneva Austria GmbH","briefTitle":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","officialTitle":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":null,"completion":"2006-11","firstPosted":"2008-01-30","resultsPosted":"2012-11-20","lastUpdate":"2024-03-21"},"enrollment":2675,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"Japanese Encephalitis purified inactivated vaccine (IC51)","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged \\> or = 18 years","primaryOutcome":{"measure":"Safety and Tolerability up to Day 56","timeFrame":"Day 56","effectByArm":[{"arm":"IC51","deltaMin":58.9,"sd":null},{"arm":"Placebo","deltaMin":56.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":1993},"commonTop":["Headache","Myalgia","Influenza Like Illness","Fatigue","Nausea"]}}